WCAMG
CASC

Woodard & Company Asset Management Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Woodard & Company Asset Management Group’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-27
Closed – – 250
2017
Q4 		$0 Buy
+27
New +$111 ﹤0.01% 242

Woodard & Company Asset Management Group's CASC Position: Q1 2018 in Review

Woodard & Company Asset Management Group sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 27 shares.

Woodard & Company Asset Management Group first reported a position in CASC in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Woodard & Company Asset Management Group reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Woodard & Company Asset Management Group sold 27 Cascadian Therapeutics, Inc. shares in Q1 2018.
  • Woodard & Company Asset Management Group first reported a position in Cascadian Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Woodard & Company Asset Management Group's Cascadian Therapeutics, Inc. position peaked at $0 in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Woodard & Company Asset Management Group's 13F filing for Q1 2018, filed 27 Apr 2018.